



KineMed Announces Presentation at the American Heart Association's Scientific Sessions 2005 Conference

EMERYVILLE, Calif., November 10, 2005 -- KineMed, Inc., a platform-based drug development and advanced medical diagnostics company, announced today that a poster presentation on the Company's technology will take place on November 15th at the American Heart Association Scientific Sessions 2005 which will be held in Dallas Texas. The presentation information is as follows:

Date: Tuesday, November 15, 2005
Time: 3:30-5:00 pm, Central Standard Time
Location: Dallas Convention Center Hall E
Title of Presentation:
"The Stable Isotope Method for the Measurement of Reverse Cholesterol Transport"; the presentation will take place during the session entitled, HDL Metabolism (session # APS.14.3M).

Background on reverse cholesterol transport

Higher plasma concentrations of high-density lipoprotein (HDLc) are associated with lower cardiovascular risk. The cardioprotective effects of HDLc are based on epidemiologic studies, animal models, and some prospective clinical therapeutic trials.

The most widely accepted mechanistic explanation for these cardioprotective actions of HDLc is its role in reverse cholesterol transport (RCT). This refers to the process by which cholesterol is mobilized from tissues, carried through the blood and excreted from the body in the form of fecal sterols. RCT is the only pathway by which cholesterol can be removed from the body and, therefore, represents a key therapeutic target, particularly for reversing existing arteriosclerotic lesions.

About KineMed, Inc.

KineMed, Inc. provides a proprietary set of tools for measuring the dynamics of molecular and cellular response to drugs in the intact organism, both in animals and humans. KineMed's technology is ideally suited to enable the discovery of entirely new, unanticipated uses for compounds (an approach called repurposing or repositioning) by screening for activity in vivo across a wide variety of disease states. The breadth of therapeutic targets covered by KineMarker(TM) assays allows high-throughput screening in conditions beyond those typically evaluated. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.

For further information about KineMed, please visit: <http://www.kinemed.com>

CONTACT: Lisa Misell, Ph.D., Vice President of Business Development of KineMed, +1-510-655-6525, ext. 117, or Media: Justin Jackson, Burns McClellan, +1-212-213-0006, jjackson@burnsmc.com, for KineMed, Inc.